Description

QUALITATIVE AND QUANTITATIVE COMPOSITION :

18.0 mg of oxycodone and 20 mg of oxycodone hydrochloride are contained in each 20 mg tablet.

Excipient(s) with a recognized impact:

There is 59.3 mg of lactose monohydrate in each 20 mg tablet.

Contraindications:

• hypersensitivity to any of the additives or the active ingredient.

• severe long-term blockage of the airways.

• The pulmonale cor

• serious asthma in the bronchi

• serious hypoxia and breathing problems.

• elevated blood gas concentrations (hypercarbia)

• diarrhea paralyzed,

• head trauma.

Special warnings and precautions for use:

When prescribing oxycodone to individuals who are severely impaired in their ability to breathe, their liver or kidneys, their myxoedema, hypothyroidism, Addison’s disease, toxic psychosis, prostate hypertrophy, adrenocortical insufficiency, alcoholism, delirium tremens, diseases of the biliary tract, pancreatitis, inflammatory bowel disorders, hypotension, hypovolaemia, raised intracranial pressure, intracranial lesions, head injury (due to the danger of higher intracranial pressure), sleep apnea, or individuals taking benzodiazepines, similar drugs (including alcohol) or MAO inhibitors should proceed with caution.

Interaction with other medicinal products and other forms of interaction:

• Due to the additive CNS depressant effect, using opioids concurrently with the new sedative medications like benzodiazepines or similar drugs increases the risk of sedation, respiratory depression, coma, and death.

• There should be restrictions on the amount and length of concurrent use.

• Serotonin toxicity may result from concurrent use of oxycodone and serotonin-blocking medications, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).

Overdose:

• Acute oxycodone overdose symptoms may include breathing difficulties, a low blood pressure miosis, and illusions. Dystonia, cardiac arrest, oedema of the lungs, and heart failure resulting in drowsiness or deepening coma.
• Patients should let others know about the warning signs and symptoms of an overdose.
• Establishing an airway patent should be the main focus of treatment for oxycodone overdose.

• If the patient is unconscious or has breathing problems as a result of a massive overdose, give them naloxone via vein. If there’s no improvement after two

minutes, repeat the dose.

Additional/other considerations:

• If a significant amount has been consumed in less than an hour, take note of activated charcoal, as long as the breathing is protected.
• For up to 12 hours following management, OxyContin tablets will keep dispensing oxycodone and add to its burden; as a result, the treatment of oxycodone overdose should be adjusted.

Conclusion:

Respiratory and pulmonary disorders are contraindications for oxycodone-containing OxyContin 20mg. Drug interactions and a number of other health concerns call for caution. Overdose symptoms necessitate prompt medical attention as well as certain measures.